Overview Dividends

(AXSM) Axsome Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Antidepressant, Wake-Promoting, Migraine, Alzheimer, Narcolepsy

AXSM EPS (Earnings per Share)

EPS Growth (3Y CAGR): 18.15%
EPS Trend (3Y Correlation): -1.5%

AXSM Revenue

Revenue Growth (3Y CAGR): 103.08%
Revenue Trend (3Y Correlation): 86.7%

Risk via 10d forecast
Volatility	41.3%
Value at Risk 5%th	62.4%

Reward
Sharpe Ratio	1.10
Alpha Jensen	44.03

Character
Hurst Exponent	0.623
Beta	0.480

Drawdowns 3y
Max DD	36.45%
Mean DD	14.78%

Description: AXSM Axsome Therapeutics November 05, 2025

Axsome Therapeutics (NASDAQ: AXSM) is a U.S.-based biopharma that targets central nervous system (CNS) disorders. Its commercial lineup includes Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, and Symbravo (AXS-07), a rapid-onset migraine therapy that combines meloxicam and rizatriptan.

The pipeline features several late-stage candidates: AXS-05 (dextromethorphan-bupropion) has finished Phase III for Alzheimer’s disease agitation and Phase II for smoking cessation; AXS-12 (reboxetine) completed Phase III for narcolepsy; AXS-14 (esreboxetine) wrapped Phase III for fibromyalgia; and Solriamfetol is in Phase III trials for ADHD, major depression, binge-eating disorder, and shift-work sleepiness. Axsome also maintains a research collaboration with Duke University to evaluate AXS-05 in smoking cessation.

As of the latest quarter (Q2 2024), Axsome reported $68 million in total revenue, driven primarily by Sunosi and Auvelity, and held $550 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates. The CNS therapeutics market is expanding at a 6-7 % CAGR, buoyed by aging demographics and unmet needs in depression and sleep disorders-trends that underpin Axsome’s growth thesis. For a deeper dive into the company’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can help surface the most material assumptions.

AXSM Stock Overview

Market Cap in USD	6,965m
Sub-Industry	Pharmaceuticals
IPO / Inception	2015-11-19
Return 12m vs S&P 500	32.9%
Analyst Rating	4.74 of 5

AXSM Dividends

Currently no dividends paid

AXSM Growth Ratios

CAGR	36.88%
CAGR/Max DD Calmar Ratio	1.01
CAGR/Mean DD Pain Ratio	2.49
Current Volume	542.1k
Average Volume	508.2k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-229.5m TTM) > 0 and > 6% of Revenue (6% = 33.7m TTM)

FCFTA -0.15 (>2.0%) and ΔFCFTA 8.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 36.53% (prev 83.59%; Δ -47.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.15 (>3.0%) and CFO -101.0m > Net Income -229.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (50.0m) change vs 12m ago 3.91% (target <= -2.0% for YES)

Gross Margin 91.86% (prev 91.09%; Δ 0.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 91.21% (prev 60.28%; Δ 30.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -27.30 (EBITDA TTM -199.2m / Interest Expense TTM 7.59m) >= 6 (WARN >= 3)

Altman Z'' -8.73

(A) 0.31 = (Total Current Assets 565.3m - Total Current Liabilities 360.3m) / Total Assets 669.2m

(B) -1.91 = Retained Earnings (Balance) -1.28b / Total Assets 669.2m

warn (B) unusual magnitude: -1.91 — check mapping/units

(D) -2.15 = Book Value of Equity -1.28b / Total Liabilities 595.5m

Total Rating: -8.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.50

1. Piotroski 3.0pt = -2.0

2. FCF Yield -1.47% = -0.74

3. FCF Margin -18.00% = -6.75

4. Debt/Equity 2.96 = -0.72

5. Debt/Ebitda 0.54 = 2.28

6. ROIC - WACC (= -92.45)% = -12.50

7. RoE -357.2% = -2.50

8. Rev. Trend 86.67% = 6.50

9. EPS Trend -1.48% = -0.07

What is the price of AXSM shares?

As of November 12, 2025, the stock is trading at USD 139.61 with a total of 542,073 shares traded.
Over the past week, the price has changed by +3.47%, over one month by +15.24%, over three months by +34.29% and over the past year by +53.45%.

Is Axsome Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Axsome Therapeutics (NASDAQ:AXSM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 33.50 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AXSM is around 163.12 USD . This means that AXSM is currently undervalued and has a potential upside of +16.84% (Margin of Safety).

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.

Strong Buy: 14
Buy: 5
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the AXSM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	181.5	30%
Analysts Target Price	181.5	30%
ValueRay Target Price	180.3	29.2%

AXSM Fundamental Data Overview November 11, 2025

Market Cap USD = 6.96b (6.96b USD * 1.0 USD.USD)
P/E Forward = 370.3704
P/S = 12.4086
P/B = 81.9047
Beta = 0.48
Revenue TTM = 561.3m USD
EBIT TTM = -207.3m USD
EBITDA TTM = -199.2m USD
Long Term Debt = 180.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 73.2m USD (from shortTermDebt, last quarter)
Debt = 218.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -106.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.86b USD (6.96b + Debt 218.6m - CCE 325.3m)
Interest Coverage Ratio = -27.30 (Ebit TTM -207.3m / Interest Expense TTM 7.59m)
FCF Yield = -1.47% (FCF TTM -101.0m / Enterprise Value 6.86b)
FCF Margin = -18.00% (FCF TTM -101.0m / Revenue TTM 561.3m)
Net Margin = -40.89% (Net Income TTM -229.5m / Revenue TTM 561.3m)
Gross Margin = 91.86% ((Revenue TTM 561.3m - Cost of Revenue TTM 45.7m) / Revenue TTM)
Gross Margin QoQ = 93.03% (prev 91.04%)
Tobins Q-Ratio = 10.25 (Enterprise Value 6.86b / Total Assets 669.2m)
Interest Expense / Debt = 0.51% (Interest Expense 1.12m / Debt 218.6m)
Taxrate = -0.03% (negative due to tax credits) (85.0k / -287.1m)
NOPAT = -207.4m (EBIT -207.3m * (1 - -0.03%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.57 (Total Current Assets 565.3m / Total Current Liabilities 360.3m)
Debt / Equity = 2.96 (Debt 218.6m / totalStockholderEquity, last quarter 73.7m)
Debt / EBITDA = 0.54 (negative EBITDA) (Net Debt -106.7m / EBITDA -199.2m)
Debt / FCF = 1.06 (negative FCF - burning cash) (Net Debt -106.7m / FCF TTM -101.0m)
Total Stockholder Equity = 64.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.30% (Net Income -229.5m / Total Assets 669.2m)
RoE = -357.2% (Net Income TTM -229.5m / Total Stockholder Equity 64.3m)
RoCE = -84.64% (EBIT -207.3m / Capital Employed (Equity 64.3m + L.T.Debt 180.7m))
RoIC = -84.89% (negative operating profit) (NOPAT -207.4m / Invested Capital 244.3m)
WACC = 7.56% (E(6.96b)/V(7.18b) * Re(7.78%) + D(218.6m)/V(7.18b) * Rd(0.51%) * (1-Tc(-0.00)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 2.80%
Fair Price DCF = unknown (Cash Flow -101.0m)
EPS Correlation: -1.48 | EPS CAGR: 18.15% | SUE: -0.33 | # QB: 0
Revenue Correlation: 86.67 | Revenue CAGR: 103.1% | SUE: 2.02 | # QB: 2

Additional Sources for AXSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle